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Material and methods The effect of NHI-Glc-2 on cell growth
is tested in our primary PDAC cancer cell cultures, character-
ised for their hypoxic signature and LDH-A/GLUT-1 expres-
sion levels by next-generation sequencing. Inhibition of cell
and tumour growth was evaluated by the SRB assay, 3D sphe-
roid-cultures and with an orthotopic bioluminescent in vivo
model. Additionally, LDH-A enzyme activity inhibition and the
effect on the glycolytic rate by NHI-Glc-2 were assessed by
spectrophotometry and with the Seahorse XF analyzer,
respectively.
Results and discussions NHI-Glc-2 is capable of inhibiting
PDAC cell growth in, especially in hypoxia, in nanomolar
range and shows a synergistic effect with gemcitabine. In 3D
cultures NHI-Glc-2 disrupts spheroid integrity, and preliminary
in vivo studies show promising results.
Conclusion Lactate dehydrogenase A is a viable target in
PDAC, and the novel LDH-A inhibitor showed improved
pharmacological effect in normoxic and hypoxic PDAC cells
compared to NHI-1 and NHI-2. Moreover, this compound
displays a synergistic cytotoxic activity with gemcitabine, offer-
ing an innovative tool in hypoxic tumours.
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Introduction Pancreatic cancer is one of the deadliest cancer
types with very poor survival rates and limited treatment
options. Therefore, novel treatments are urgently needed.
Monoclonal antibody (mAb) technology is an excellent tool for
the discovery of overexpressed cell surface tumour antigens and
development of mAb-based products for use in diagnosis and
treatment of cancer. While several mAbs have been approved for
the treatment of a wide range of cancers, none have been
approved for pancreatic cancer yet. The aim of our study was to
develop novel mAbs against overexpressed cell surface antigens
on pancreatic cancer cells for use in cancer diagnosis and
therapy.
Material and methods Novel mAbs were generated against
CFPAC-1 cells using hybridoma technology and those directed
against overexpressed cell surface antigens were selected and
purified by affinity chromatography. Further characterisation
was performed by ELISA, flow cytometry, cell proliferation
and migration assays, internalisation studies, immunoprecipita-
tion and mass spectrometry, immunohistochemistry and West-
ern blotting.
Results and discussions We developed two novel mouse mAbs
named KU44.13A and KU44.22B that were found to target
CD26 and integrin alpha-3 respectively. Integrin alpha-3 was
found to be widely overexpressed in human pancreatic cancer
cell lines by ELISA and flow cytometry. Treatment with mAb
KU44.22B induced receptor downregulation and internalisation
and inhibited the growth in vitro of the human pancreatic
cancer cell line Capan-2 with an IC50 of 4.5 nM.
Paradoxically, treatment with this antibody increased the
migration of BxPC-3 and CFPAC-1 cancer cell lines. CD26
expression, in turn, was limited to pancreatic cancer cell lines
derived from ascites (HPAF-II and AsPC-1). Treatment with
targeting mAb KU44.13A did not have any effect on cell pro-
liferation, migration or receptor downregulation and internal-
isation. While neither of the two mAbs immunodetected the
target antigen by Western blot, they were useful for immuno-
histochemical detection of the target antigens in formalin-fixed
paraffin-embedded tumour sections.
Conclusion We believe these two novel mAbs are useful tools
for investigating the relative expression, prognostic significance
and predictive value of CD26 and integrin alpha-3 in patients
with pancreatic cancer. Further studies are warranted to eluci-
date the therapeutic potential of these novel mAbs including
their humanised or conjugated versions, in patients pancreatic
and other types of cancer.
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Introduction Adoptive cell therapy using genetically engineered
chimeric antigen receptor (CAR) T cells has demonstrated unpre-
cedented potency in B cell malignancies, and offers new hope
for curative responses in patients suffering from cancer. How-
ever, the manufacturing process for CAR T cells is very complex
and has extensive demands on personnel and infrastructure,
which is a major obstacle for their routine clinical use. To over-
come these hurdles, the CliniMACS Prodigy allows generation
of CAR T cells in a single automated and closed system.
Material and methods CliniMACS Prodigy
MACSQuant Analyzer
MACS Antibodies
Results and discussions For assessment of CAR T cells during
cell manufacturing and patient immunomonitoring we devel-
oped a set of different flow cytometric assays. These assays
will be used for 1) in-process control, QC release testing, and
concomitant research during the manufacturing process, and
2) for determination of CAR T cell persistance and phenotyp-
ing during patient immunomonitoring. Among others these
assays allow to determine the general immune cell composi-
tion, CAR transduction efficiency, and further functional CAR
T cell phenotypes like differentiation, activation, or exhaustion
status.
For identification of CAR T cells we developed CAR detec-
tion reagents that specifically bind to the antigen-recognition
domain of the receptor. Thus, these detection reagents dis-
criminate between various CAR constructs, and can be used
for enumeration of CAR T cells during manufacturing and
immunomonitoring.
For all flow assays mentioned above so-called Express
Modes have been programmed, that allow an automated
acquisition and analysis of stained samples on MACSQuant
Analyzers. These Express Modes feature predefined experiment
settings and analysis templates, and apply a fully automated
gating strategy that adapts for each individual data file. This
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